JP5868869B2 - 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム - Google Patents

光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム Download PDF

Info

Publication number
JP5868869B2
JP5868869B2 JP2012543222A JP2012543222A JP5868869B2 JP 5868869 B2 JP5868869 B2 JP 5868869B2 JP 2012543222 A JP2012543222 A JP 2012543222A JP 2012543222 A JP2012543222 A JP 2012543222A JP 5868869 B2 JP5868869 B2 JP 5868869B2
Authority
JP
Japan
Prior art keywords
photosensitizer
photodynamic therapy
nanoparticles
plga
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012543222A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513610A5 (enExample
JP2013513610A (ja
Inventor
ランガー、クラウス
ノブロフ、トーマス
レーダー、ベアーテ
プルース、アンネグレット
アルブレヒト、フォルカー
グレーフェ、スザンナ
ヴィーエ、アルノ
ブリーセン、ハーゲン フォン
ブリーセン、ハーゲン フォン
レーブ、カリン
ワグナー、シルビア
Original Assignee
バイオリテック ファーマ マーケティング リミテッド
バイオリテック ファーマ マーケティング リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオリテック ファーマ マーケティング リミテッド, バイオリテック ファーマ マーケティング リミテッド filed Critical バイオリテック ファーマ マーケティング リミテッド
Publication of JP2013513610A publication Critical patent/JP2013513610A/ja
Publication of JP2013513610A5 publication Critical patent/JP2013513610A5/ja
Application granted granted Critical
Publication of JP5868869B2 publication Critical patent/JP5868869B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012543222A 2009-12-11 2010-12-08 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム Expired - Fee Related JP5868869B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28589509P 2009-12-11 2009-12-11
US61/285,895 2009-12-11
US12/941,447 2010-11-08
US12/941,447 US20110275686A1 (en) 2009-12-11 2010-11-08 Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)
PCT/US2010/059367 WO2011071970A2 (en) 2009-12-11 2010-12-08 Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)

Publications (3)

Publication Number Publication Date
JP2013513610A JP2013513610A (ja) 2013-04-22
JP2013513610A5 JP2013513610A5 (enExample) 2014-08-14
JP5868869B2 true JP5868869B2 (ja) 2016-02-24

Family

ID=44146154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012543222A Expired - Fee Related JP5868869B2 (ja) 2009-12-11 2010-12-08 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム

Country Status (7)

Country Link
US (1) US20110275686A1 (enExample)
EP (1) EP2509633B1 (enExample)
JP (1) JP5868869B2 (enExample)
CN (2) CN106913533A (enExample)
BR (1) BR112012013951A2 (enExample)
CA (1) CA2784005C (enExample)
WO (1) WO2011071970A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211283B2 (en) * 2009-12-11 2015-12-15 Biolitec Pharma Marketing Ltd Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
WO2013012628A2 (en) * 2011-07-15 2013-01-24 The University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
JP2013094135A (ja) * 2011-11-02 2013-05-20 Waseda Univ 人工ナノ材料の安全性を評価する方法
CN103169968B (zh) * 2013-03-12 2014-11-26 中国科学院理化技术研究所 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用
US10188601B2 (en) * 2013-09-22 2019-01-29 Brenda Laster Continuous long-term controlled release of telomerase inhibitors
CN103933568B (zh) * 2014-05-12 2016-03-30 南京师范大学 一种水溶性竹红菌素plga纳米粒及其制备方法
EP3201201B1 (en) 2014-09-30 2022-01-26 biolitec unternehmensbeteiligungs II AG Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
CN106620893B (zh) * 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
WO2017019792A1 (en) * 2015-07-27 2017-02-02 The Texas A&M University System Surface active nanosystems
CN105343878B (zh) * 2015-11-30 2018-10-19 中国人民解放军第三军医大学第三附属医院 还原敏感型水溶性分子靶向光敏剂及其制备方法和应用
EP3210626B1 (en) 2016-02-26 2024-11-27 biolitec Holding GmbH & Co KG Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy
CN109481418B (zh) * 2017-12-19 2022-08-19 深圳先进技术研究院 抗肿瘤纳米颗粒及其制备方法和应用
EP3626268A1 (en) 2018-09-24 2020-03-25 Westfälische Wilhelms-Universität Münster Polymer-particle light-cleavable carrier systems for photodynamic therapy
WO2020120474A1 (en) 2018-12-10 2020-06-18 Universität Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
CN113543810B (zh) * 2019-03-08 2024-02-09 北卡罗莱纳州立大学 光热疗法促进cart t细胞的肿瘤浸润和抗肿瘤活性
CN111000804B (zh) * 2019-12-05 2022-02-11 东南大学 一种甘露糖靶向的热响应铂纳米颗粒及其制备方法和应用
US20250295815A1 (en) * 2021-04-07 2025-09-25 North Carolina State University Porphyrin-hydroporphyrin compounds, compositions comprising the same and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3372558B2 (ja) * 1990-09-14 2003-02-04 中外製薬株式会社 マイクロカプセル型徐放性製剤及びその製造法
EP0851754A1 (en) 1995-09-21 1998-07-08 Novartis AG Nanoparticles in photodynamic therapy
JP3765338B2 (ja) * 1995-12-15 2006-04-12 武田薬品工業株式会社 注射用徐放性製剤の製造法
US5829448A (en) * 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
GB0001455D0 (en) * 2000-01-21 2000-03-15 Scotia Holdings Plc Porphyrins and related compounds
EP1507514B1 (en) * 2002-05-03 2007-02-14 PR Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
US7455858B2 (en) 2002-05-16 2008-11-25 Qlt Inc. Compositions and methods for delivery of photosensitive drugs
US20070148074A1 (en) 2003-01-16 2007-06-28 Mostafa Sadoqi Nanoparticle based stabilization of ir fluorescent dyes
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
US20090304803A1 (en) * 2005-06-06 2009-12-10 The General Hospital Corporation Compositions and methods relating to target-specific photodynamic therapy

Also Published As

Publication number Publication date
WO2011071970A3 (en) 2011-11-17
US20110275686A1 (en) 2011-11-10
CN102740892A (zh) 2012-10-17
BR112012013951A2 (pt) 2018-06-05
EP2509633C0 (en) 2025-06-18
CA2784005C (en) 2018-01-02
WO2011071970A2 (en) 2011-06-16
CA2784005A1 (en) 2011-06-16
JP2013513610A (ja) 2013-04-22
EP2509633B1 (en) 2025-06-18
EP2509633A4 (en) 2015-08-26
EP2509633A2 (en) 2012-10-17
CN106913533A (zh) 2017-07-04

Similar Documents

Publication Publication Date Title
JP5868869B2 (ja) 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム
Escudero et al. Photodynamic therapy: photosensitizers and nanostructures
JP5972171B2 (ja) 光力学的療法のためのヒト血清アルブミンをベースにしたナノ粒子キャリアシステム
Guan et al. Photodynamic therapy based on nanoscale metal–organic frameworks: from material design to cancer nanotherapeutics
Sun et al. Carbon dots as a novel photosensitizer for photodynamic therapy of cancer and bacterial infectious diseases: recent advances
Zhao et al. DUCNP@ Mn–MOF/FOE as a highly selective and bioavailable drug delivery system for synergistic combination cancer therapy
Xu et al. Nanoparticles in sonodynamic therapy: state of the art review
Itoo et al. Nanotherapeutic intervention in photodynamic therapy for cancer
Li et al. Cancer cell membrane camouflaged cascade bioreactor for cancer targeted starvation and photodynamic therapy
Camerin et al. The in vivo efficacy of phthalocyanine–nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma
Shiao et al. Aptamer-functionalized gold nanoparticles as photoresponsive nanoplatform for co-drug delivery
Bayir et al. Mesoporous silica nanoparticles in recent photodynamic therapy applications
Li et al. Sequential protein-responsive nanophotosensitizer complex for enhancing tumor-specific therapy
Tu et al. Multifunctional ZnPc-loaded mesoporous silica nanoparticles for enhancement of photodynamic therapy efficacy by endolysosomal escape
Yang et al. Metal–organic framework nanoparticles with near-infrared dye for multimodal imaging and guided phototherapy
KR101035269B1 (ko) 고분자 유도체-광감작제 복합체를 이용한 새로운 광역학치료제
EP2440247B1 (en) Targeted nano-photomedicines for photodynamic therapy of cancer
CN112870191B (zh) 一种金属有机框架zif-8包裹普鲁士蓝负载槲皮素的纳米粒的制备方法
CN105283174B (zh) 靶向增强的抗癌纳米颗粒及其制备方法
Chouikrat et al. Non polymeric nanoparticles for photodynamic therapy applications: recent developments
Le et al. Emerging NIR light-responsive delivery systems based on lanthanide-doped upconverting nanoparticles
JP2013513610A5 (enExample)
Bœuf-Muraille et al. Evaluation of mTHPC-loaded PLGA nanoparticles for in vitro photodynamic therapy on C6 glioma cell line
Kim et al. pH-Sensitive carbon dots for enhancing photomediated antitumor immunity
Harvey et al. Recent advances in nanoscale metal–organic frameworks towards cancer cell cytotoxicity: an overview

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140626

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160106

R150 Certificate of patent or registration of utility model

Ref document number: 5868869

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

LAPS Cancellation because of no payment of annual fees
R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350